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A B S T R A C T
Background
Nebulised surfactant has the potential to deliver surfactant to the infant lung with the goal of avoiding endotracheal intubation and
ventilation, ventilator-induced lung injury and bronchopulmonary dysplasia (BPD).
Objectives
To determine the effect of nebulised surfactant administration either as prophylaxis or treatment compared to placebo, no treatment or
intratracheal surfactant administration on morbidity and mortality in preterm infants with, or at risk of, respiratory distress syndrome
(RDS).
Search methods
Searches were performed of CENTRAL (The Cochrane Library, January 2012), MEDLINE and PREMEDLINE (1950 to January
2012), EMBASE (1980 to January 2012) and CINAHL (1982 to January 2012), as well as proceedings of scientific meetings, clinical
trial registries, Google Scholar and reference lists of identified studies. Expert informants and surfactant manufacturers were contacted.
Selection criteria
Randomised, cluster-randomised or quasi-randomised controlled trials of nebulised surfactant administration compared to placebo, no
treatment, or other routes of administration (laryngeal, pharyngeal instillation of surfactant before the first breath, thin endotracheal
catheter surfactant administration or intratracheal surfactant instillation) on morbidity and mortality in preterm infants at risk of RDS.
We considered published, unpublished and ongoing trials.
Data collection and analysis
Two review authors independently assessed studies for eligibility and quality, and extracted data.
Main results
No studies of prophylactic or early nebulised surfactant administration were found. A single small study of late rescue nebulised
surfactant was included. The study is of moderate risk of bias. The study enrolled 32 preterm infants born < 36 weeks’ gestation with
RDS on nasal continuous positive airway pressure (nCPAP). The study reported no significant difference between nebulised surfactant
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administration compared to no treatment groups in chronic lung disease (risk ratio (RR) 5.00; 95% confidence interval (CI) 0.26
to 96.59) or other outcomes (oxygenation 1 to 12 hours after randomisation, need for mechanical ventilation, days of mechanical
ventilation or continuous positive airways pressure (CPAP) or days of supplemental oxygen). No side effects of the nebulised surfactant
therapy or aerosol inhalation were reported.
Authors’ conclusions
There are insufficient data to support or refute the use of nebulised surfactant in clinical practice. Adequately powered trials are required
to determine the effect of nebulised surfactant administration for prevention or early treatment of RDS in preterm infants. Nebulised
surfactant administration should be limited to clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
There is insufficient evidence from randomised controlled trials to guide the use of nebulised surfactant in preterm infants at risk of
respiratory distress syndrome.
Respiratory distress syndrome is caused by a deficiency of the naturally occurring lining chemicals of the lung (surfactant) and occurs
mainly in infants born before term (37 weeks’ gestation). Usual treatment includes instilling artificial surfactant directly into the
newborn infant’s trachea followed by mechanical ventilation. However, this process can lead to lung injury, which can affect the infant’s
long-term health. A potential alternative strategy is to use nebulised surfactant. This procedure has the potential to reduce the need for
tracheal intubation after birth and subsequent lung damage caused by mechanical ventilation. This review found one small randomised
controlled trial of nebulised surfactant administration in preterm infants with respiratory distress syndrome that reported no beneficial
effect of nebulised surfactant. This study is too small and has a moderate risk of bias making conclusions uncertain. In view of the
encouraging results from other observational studies, high-quality trials of nebulised surfactant in preterm infants with or at risk of
respiratory distress syndrome are justified.
B A C K G R O U N D
Description of the condition
Respiratory distress syndrome (RDS) results from pulmonary sur-
factant deficiency and is an important cause of morbidity and mor-
tality in preterm infants. Randomised controlled trials (RCTs) and
meta-analyses have demonstrated the efficacy of surfactant ther-
apy in both prevention and treatment of infants with or at risk for
RDS. A wide variety of surfactant preparations have been studied.
These include synthetic surfactants (Soll 2000; Soll 2010) and
surfactants derived from animal sources (natural surfactants) (Soll
1997; Seger 2009). Although both synthetic and animal-derived
surfactant preparations are effective, clinical trials suggest that an-
imal-derived surfactant preparations (Soll 2001) may be more ef-
fective than protein-free synthetic surfactant (Tooley 1987). Fur-
thermore, clinical trials have shown earlier treatment may be supe-
rior to selective use of surfactant in preventing morbidity and mor-
tality in preterm infants (Yost 2000; Stevens 2007; Rojas-Reyes
2012), and a multiple-dose is superior to a single-dose strategy
(Soll 2009). New protein-containing synthetic surfactants have
been successfully tested (Pfister 2007; Pfister 2009) although these
preparations are not currently available for clinical use.
Despite the benefits of surfactant, many infants develop bron-
chopulmonary dysplasia (BPD) and chronic lung disease (CLD).
Although the aetiology of CLD in preterm infants is multifactorial
(Allen 2003), ventilator-induced lung injury (VILI) remains one
of the main implicated risk factors (Coalson 1999; Clark 2000).
VILI has been shown to start with only a few resuscitative positive
pressure ventilation (PPV) breaths (Grossmann 1986; Björklund
1997; Flecknoe 2008; O’Reilly 2008).
Both surfactant prophylaxis and therapy necessitate endotracheal
intubation to facilitate surfactant administration. Although sur-
factant by itself is an established effective intervention for either
prevention or treatment of RDS, the endotracheal intubation and
PPV that follow are not without side effects.
Endotracheal intubation is a potentially traumatic procedure of-
ten performed without optimal pain management (Sarkar 2006).
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It may be accompanied by significant haemodynamic instability
including hypoxia, bradycardia, blood pressure fluctuation and
intracranial pressure increase (Marshall 1984; Ghanta 2007). In-
tubation is inevitably associated with colonisation of the trachea,
retained secretions resulting in collapse, differential aeration and
high resistance to air flow resulting in increased work of breathing,
potentially leading to nosocomial pneumonia and sepsis (Young
2005; Aly 2008). Intubation is associated with an inflammatory
process that can lead to lung injury and BPD (Young 2005). Cur-
rent evidence suggests PPV of an immature, surfactant-deficient
lung is harmful and may exacerbate the development of BPD
(Björklund 1997; Van Marter 2000). Björklund 1997 reported
resuscitation of surfactant-deficient immature lambs with as few
as six breaths damages the lung and blunts the therapeutic effect
of subsequent surfactant replacement. Grossmann 1986 reported
similar results. Flecknoe 2008 reported that just six hours of ven-
tilation is enough to cause marked airway epithelial injury in very
preterm and near-term foetal sheep. O’Reilly 2008 reported that
ventilator-induced injury extends to involve the conducting air-
ways as well.
One approach for surfactant administration is the InSurE (INtu-
bation-SURfactant-Extubation) technique pioneered by Victorin
and Verder (Verder 1994; Victorin 1990). Review of trials found
early surfactant replacement therapy with prompt extubation to
nasal continuous positive airway pressure (nCPAP), as in the In-
SurE technique, is associated with less need for mechanical ven-
tilation, lower incidence of BPD and fewer air leak syndromes
when compared with later selective surfactant replacement and
continued mechanical ventilation with extubation from low ven-
tilator support (Stevens 2007). However, the limited data avail-
able show the InSurE procedure to be associated with a trend for
decreased cerebral oxygenation, higher cerebral oxygen extraction
and decreased electric brain activity (Hellstrom-Westas 1992; van
de Berg 2009). Furthermore, the InSurE procedure may need to
be repeated if the first dose of surfactant was not sufficiently effec-
tive (Bohlin 2007), leading to additional risk of brain damage.
The main strategy used to avoid endotracheal intubation and PPV
in premature infants is application of nCPAP or continuous dis-
tending pressure (CDP) immediately following birth (Kamper
1999; Ho 2002a; Ho 2002b). Some studies suggest CDP may lead
to less CLD compared to elective intubation, surfactant and PPV
(Aly 2001; DeKlerk 2001; SUPPORT Study Group 2010; Dunn
2011). Similarly, nasal intermittent positive pressure ventilation
(NIPPV) has been shown to increase the likelihood of avoiding in-
tubation and mechanical ventilation, reduce frequency of apnoea
and a trend for less CLD without an increase in adverse effects
(Lemyre 2002; Davis 2008). Although CDP and NIPPV strategies
avoid endotracheal intubation and PPV, it precludes surfactant
administration, which is a standard and confirmed treatment for
RDS. Furthermore, CDP, NIPPV and InSurE may fail in 25% to
50% of preterm infants (Reininger 2005; Kugelman 2007; Morley
2008).
Description of the intervention
Non-invasive methods of surfactant administration have the po-
tential to reduce the need for intubation and endotracheal surfac-
tant administration. Potential strategies include:
1. intra-amniotic instillation (Petrikovsky 1995);
2. pharyngeal instillation (Kattwinkel 2004);
3. administration via laryngeal mask airway surfactant
(Trevisanuto 2005);
4. administration via thin endotracheal catheter without
intermittent positive pressure ventilation (IPPV) (Kribs 2007;
Kribs 2010; Dargaville 2011);
5. nebulised surfactant administration in spontaneously
breathing infants (Jorch 1997).
This review will focus on nebulised surfactant administration.
The typical protocol for nebulised surfactant administration (Finer
2006) involves using an aerosol generator with nebulised surfac-
tant administered via a nCPAP system, tight face-mask system or
nasopharyngeal tube. Aerosol generators include jet nebulisers, ul-
trasonic nebulisers and vibrating membrane nebulisers. There is
an aerosolised form of peptide-containing surfactant available but
other forms of surfactant have also been tried.
In preterm animal models and animal models of induced lung
injury, nebulised surfactant improved ventilation and lung me-
chanics, even with minimal deposition in the lungs (Lewis 1991;
Lewis 1993a; Lewis 1993b; Lewis 1993c; Wolfson 2008). Johnson
2006 and Johnson 2007 measured surface activity of aerosolised
lucinactant in vitro (using a pulsating bubble surfactometer) and
in vivo (using a foetal rabbit bioassay). In both models, lucinac-
tant retained its activity after capillary aerosol generation. Similar
findings have been described for bovine surfactant (Jorch 1994).
On average 0.08% to 15% of total administered aerosolised sur-
factant could be recovered in animal models (Lewis 1993c; Fok
1998; Bahlmann 2000). Multiple factors are reported to influence
aerosol surfactant dose delivery, including patient weight or size;
minute ventilation (Cole 2000), aerosol flow and patient peak in-
spiratory flow; aerosol particle size (as large as possible to avoid
potential exhalation yet small enough to bypass the oropharynx)
(Mazela 2007); aerosol generator used and type of surfactant (Fok
1998). An ultrasonic nebuliser and colfosceril palmitate (Exosurf )
have been shown to have higher deposition than a jet nebuliser
and beractant (Survanta) (Fok 1998).
Small human neonatal pilot and case series studies demonstrate
conflicting results. Reports include studies showing that nebulised
surfactant may reduce the need for endotracheal intubation and
is well tolerated (Jorch 1997; Finer 2006), with no adverse effects
reported apart from transient oxygen desaturation during dosing,
and another report that nebulised surfactant had no beneficial
effects (Arroe 1998).
How the intervention might work
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The nebulised surfactant administration technique is designed
to emit a continuous dense surfactant microaerosol of diameter
less than 2 µm ideal for deep lung deposition. The technique is
designed to avoid endotracheal intubation yet offer the benefits
of surfactant administration. Combining this surfactant adminis-
tration strategy with antenatal corticosteroid administration and
CDP may offer potential synergy to treat RDS, avoiding both en-
dotracheal intubation and PPV, and reducing lung injury that may
lead to BPD. In a variety of animal models of induced lung injury,
nebulised surfactant improved pulmonary mechanics, lung struc-
ture integrity, and reduced lung inflammation, even with minimal
deposition in the lungs (Lewis 1991; Lewis 1993a; Wolfson 2008).
However, other studies have showed that nebulised surfactant did
not improve pulmonary parameters (Fok 1998).
Why it is important to do this review
Despite significant advances in neonatal intensive care, CLD re-
sults in a significant health burden to preterm infants born at
less than 32 weeks’ gestation who received mechanical ventila-
tion. CLD results in substantial neonatal and infant morbidity
and health resource utilisation (Allen 2003). CLD is associated
with chronic respiratory difficulties (Kilbride 2003; Doyle 2006),
prolonged and recurrent hospitalisation (Chye 1995), neurode-
velopmental disability including cerebral palsy, neurosensory and
motor disability (Skidmore 1990; Hughes 1999; Majnemer 2000)
and poor cognitive outcome (Hughes 1999). CLD has a major
impact on the daily life of families that persists beyond the neona-
tal period (Korhonen 1999). Nebulised surfactant is a physiolog-
ical and logical technique with the potential benefit of avoiding
ventilation, VILI and BPD.
O B J E C T I V E S
To determine the effect of nebulised surfactant administration
compared to placebo, no treatment or intratracheal surfactant in-
stillation on morbidity or mortality, or both, in preterm infants at
risk for or having RDS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published, unpublished and ongoing RCTs; quasi-randomised tri-
als regardless of unit of allocation (individual or cluster) were con-
sidered to be eligible for inclusion in this review.
Types of participants
Preterm infants (less than 37 weeks’ gestation) at risk for or having
RDS of any severity and at any postnatal age as included in the
trials.
We defined prophylactic surfactant therapy as all treatment strate-
gies in which the intent was to treat a preterm infant based on the
risk of RDS within the first hour of life. We defined risk of RDS
as gestational age of less than 32 weeks or birthweight less than
1250 g.
We defined treatment of established disease (’rescue therapy’) as
treatment of a preterm infant less than 37 weeks’ gestational age
requiring respiratory support and having signs and symptoms of
RDS.
Types of interventions
Nebulised surfactant administration at any dose, using any type of
surfactant (synthetic, animal derived or protein-containing syn-
thetic), any route of conduit (nasopharyngeal tube, laryngeal air-
way, nasal prong or face mask), and using any aerosol generator
compared with either placebo, no treatment or intratracheal in-
stilled surfactant. We planned to perform separate comparisons
for all above comparative groups if trial data were available.
Types of outcome measures
We planned to study the following primary and secondary out-
come measures.
Primary outcomes
1. CLD defined as need for oxygen or respiratory support at
36 weeks’ postmenstrual age (PMA) (Shennan 1988).
2. Mortality prior to hospital discharge.
3. Neurodevelopmental disability assessed at 18 months’
postnatal age or later defined as neurological abnormality
including cerebral palsy on clinical examination, developmental
delay more than two standard deviations below population mean
on a standardised test of development, blindness (visual acuity
less than 6/60) or deafness (any hearing impairment requiring
amplification) at any time after term corrected.
Secondary outcomes
1. Intratracheal surfactant received post-intervention.
2. Mechanical ventilation.
3. Days on mechanical ventilation.
4. Days on CPAP.
5. Days of high-flow nasal cannula.
6. Days of low-flow nasal cannula.
7. Days of supplemental oxygen administration.
8. Pulmonary interstitial emphysema.
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9. Pneumothorax.
10. Use of high-frequency oscillatory ventilation (HFOV) as a
rescue treatment for respiratory distress.
11. Use of jet ventilation as a rescue treatment for respiratory
distress.
12. Use of extracorporeal membrane oxygenation (ECMO) as a
rescue treatment for respiratory distress.
13. Use of postnatal corticosteroids as rescue treatment for
respiratory distress.
14. CLD defined as need for oxygen or respiratory support at
28 days of age.
15. Use of diuretic as a prophylaxis or rescue treatment for
CLD.
16. Use of postnatal corticosteroid as a prophylaxis or rescue
treatment for CLD.
17. Use of home oxygen.
18. Asthma diagnosed by physician or challenge test.
19. Rehospitalisation for asthma.
20. Rehospitalisation for hyperactive airway disease.
21. Rehospitalisation for pneumonia.
22. Neonatal mortality (mortality at less than 28 days of age).
23. Intraventricular haemorrhage (any and severe - Papile grade
3 or 4) (Papile 1978).
24. Cystic periventricular leukomalacia.
25. Patent ductus arteriosus (PDA) - symptomatic or treated
with cyclo-oxygenase inhibitors or surgical ligation.
26. Necrotising enterocolitis (confirmed = Bell stage 2 or
greater) (Bell 1978).
27. Retinopathy of prematurity (any and severe = stage 3 or
higher) (International Committee 2005).
28. Apnoea treated with methylxanthines or respiratory
support.
29. Time to regain birth weight (days).
30. Systemic infection in first 48 hours of life.
31. Postnatal growth failure (weight less than 10th percentile at
discharge).
32. Duration of hospitalisation (days).
33. Adverse effect of the intervention including hypoxia and
bradycardia during administration.
34. Discontinuation of intervention because of side effects (e.g.
bradycardia).
Search methods for identification of studies
See: Cochrane Neonatal Group methods used in reviews.
We used the standard search strategy of the Cochrane Neona-
tal Review Group (CNRG) as outlined in The Cochrane Library.
We considered unpublished studies to be eligible for review. The
search of MEDLINE and PREMEDLINE (via OVID interface)
included the following MeSH terms and free text words: “infant,
premature, preterm, newborn, neonate”, “surfactant”, “laryngeal”,
“mask”, “airway”. We limited searches to “randomised and quasi-
randomised clinical trials” (Appendix 1). We adapted this search
strategy to suit other electronic sources like the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), EMBASE and
CINAHL. We did not apply any language restrictions.
Electronic searches
We searched the following electronic databases:
1. the Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, January 2012);
2. MEDLINE and PREMEDLINE (1950 to January 2012)
via OVID interphase;
3. EMBASE (1980 to January 2012) via OVID interphase;
4. CINAHL (1982 to January 2012) via EBSCO interphase;
5. GoogleScholar.
Searching other resources
We conducted additional searches of the following:
1. Ongoing trials in the following trial registries (searched
January 2012):
◦ ClinicalTrials.gov (U.S. National Institutes of
Health);
◦ Current Controlled Trials;
◦ Australian New Zealand Clinical Trials Registry;
◦ International Clinical Trials Registry Platform
(ICTRP).
2. Abstract of conferences from:
◦ Proceedings of the Pediatric Academic Societies
(American Pediatric Society, Society for Pediatric Research and
European Society for Pediatric Research) from 1990 to 2011
from the journal Pediatric Research and Abstracts Online;
◦ Proceedings of the European Academy of Paediatric
Societies (EAPS) (The European Society for Paediatric Research
(ESPR), the European Academy of Paediatrics (EAP) and the
European Society of Paediatric and Neonatal Intensive Care
(ESPNIC)) from 2003 to 2011 from Abstracts Online;
◦ Proceedings of the Perinatal Society of Australia and
New Zealand (PSANZ) from 1996 to 2011 (handsearch).
3. Reference lists: after reading the identified individual
studies that examined the effect of laryngeal surfactant
installation on the morbidity mortality, or both, in preterm
infants at risk of RDS, we screened the reference lists of these
papers to identify further relevant studies;
4. Personal communications with expert informants and
authors of included studies;
5. Pharmaceutical companies: we contacted the companies
that developed different types of surfactant for possible
unpublished studies using their product.
Data collection and analysis
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We used the standardised review method of the CNRG for
conducting a systematic review (http://neonatal.cochrane.org/en/
index.html). We entered and cross-checked data using Review
Manager 5.1 software (RevMan 2011).
Selection of studies
Both review authors independently reviewed the titles and ab-
stracts of potentially relevant studies against the inclusion and ex-
clusion criteria. The two review authors independently assessed
titles and the abstracts of studies identified by the search strategy
for eligibility for inclusion in this review. We retrieved full-text
versions for closer examination for eligible studies or when inad-
equate information was provided in the abstract.
Data extraction and management
Both review authors independently extracted data from the full-
text articles using a specifically designed spreadsheet matrix to
manage the information. These forms were used to decide trial
inclusion or exclusion, extract data from eligible trials and for
requesting additional published information from authors of the
original report. We entered and cross-checked data using RevMan
5.1 software (RevMan 2011). We then compared the extracted
data for any differences. If noted, we planned to resolve differences
by mutual discussion and consensus.
Assessment of risk of bias in included studies
We used the standardised review methods of the CNRG (http://
neonatal.cochrane.org/en/index.html) to assess the methodologi-
cal quality of included studies. Review authors independently as-
sessed study quality and risk of bias (see: Characteristics of included
studies) using the following criteria documented in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
1. Sequence generation: was the allocation sequence
adequately generated?
2. Allocation concealment: was allocation adequately
concealed?
3. Blinding of participants, personnel and outcome assessors
for each main outcome or class of outcomes: was knowledge of
the allocated intervention adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of
outcomes: were incomplete outcome data adequately addressed?
5. Selective outcome reporting: are reports of the study free of
suggestion of selective outcome reporting?
6. Other sources of bias: was the study apparently free of other
problems that could put it at a high risk of bias? We gave
particular attention to completeness of follow-up of all
randomised infants and to the length of follow-up studies to
identify whether any benefits claimed are robust.
When necessary, we requested additional information and clarifi-
cation of published data from the authors of individual trials. We
assessed each trial for risk of bias based on the criteria listed above
and marked as:
• low risk of bias;
• unclear risk of bias;
• high risk of bias.
We resolved discrepancies by mutual discussion and consensus.
We planned to provide levels of agreement among review authors
and details of resolution of any differences.
Measures of treatment effect
We analysed treatment effects in the individual trials using
RevMan 5.1 (RevMan 2011).
Dichotomous data
We reported dichotomous data using risk ratio (RR) and risk dif-
ference (RD), each with 95% confidence interval (CI). If there
was a statistically significant reduction in RD we then calculated
the number needed to treat for a beneficial outcome (NNTB) or
number needed to treat for a harmful outcome (NNTH) and as-
sociated 95% CI.
Continuous data
We reported continuous data using mean difference (MD) with
95% CI.
Unit of analysis issues
The unit of randomisation was the intended unit of analysis and we
expected this to be individual infants. Cluster RCTs were planned
to be included.
Cluster randomised trials
We planned to include cluster-randomised trials in the analy-
ses, along with individually randomised trials, using methods de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011) using an estimate of the intra-cluster cor-
relation coefficient (ICC) derived from the trial (if possible), or
from another source. If ICCs from other sources were used, we
planned to report this and conduct sensitivity analyses to investi-
gate the effect of variation in the ICC. If we had identifies both
cluster randomised trials and individually randomised trials, we
planned to synthesise the relevant information. We considered it
reasonable to combine the results from both if there was little het-
erogeneity between study designs, and the interaction between the
effect of intervention and the choice of randomisation unit was
considered to be unlikely.
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Dealing with missing data
We planned to obtain missing data from the study authors when
possible. If this was not possible, then we planned to conduct anal-
yses on available data (i.e. ignoring the missing data). In addition,
we planned to conduct another analysis by using an imputation
method (both best- and worst-case scenarios) and last observation
carried forward to the final assessment (LOCF) method for di-
chotomous and continuous outcome data, respectively.
For dichotomous outcomes we planned to conduct both best- and
worst-case scenarios and intention-to-treat (ITT) analysis with
imputation. We planned to compare results obtained from two
analysis options to have a better understanding of the robustness
of results relative to the different analytic approaches. We planned
to consider an imputation approach of best-case scenarios (i.e.
all missing participants in the intervention group did not experi-
ence poor outcomes (e.g. death, BPD) and all missing participants
in the control group experienced poor outcomes) and worst-case
scenarios (i.e. all missing participants in the intervention group
experienced the event and all missing participants in the control
condition did not). We planned to conduct sensitivity analysis to
compare results based on different imputation assumptions (i.e.
best- versus worst-case scenarios).
We planned to analyse missing continuous data on an end point
basis, including only participants with a final assessment, or using
LOCF if the trial authors report any LOCF data.
Assessment of heterogeneity
We used RevMan 5.1 (RevMan 2011) to assess the heterogeneity of
treatment effects between trials. We used the two formal statistics
described below.
1. The Chi2 test, to assess whether observed variability in
effect sizes between studies was greater than would be expected
by chance. Since this test has low power when the number of
studies included in the meta-analysis is small, we planned to set
the probability at the 10% level of significance.
2. The I2 statistic to ensure that pooling of data was valid. We
planned to grade the degree of heterogeneity as: 0% to 30%:
might not be important; 31% to 50%: moderate heterogeneity;
51% to 75%: substantial heterogeneity; 76% to 100%:
considerable heterogeneity.
Where there was evidence of apparent or statistical heterogeneity,
we planned to assess the source of the heterogeneity using sensitiv-
ity and subgroup analysis looking for evidence of bias or method-
ological differences between trials.
Assessment of reporting biases
We planned to investigate reporting and publication bias by ex-
amining the degree of asymmetry of a funnel plot. RevMan 5.1
(RevMan 2011) has the capability to produce this graph, which
plots the effect size estimated from each individual study against
some measure of study sample size. A symmetrical appearance of
the funnel plot will indicate absence of publication bias. Other-
wise, existence of bias is related to the degree of asymmetry.
Data synthesis
We planned to perform statistical analyses according to the
recommendations of CNRG (http://neonatal.cochrane.org/en/
index.html). We planned to analyse all infants randomised on an
ITT basis. We planned to analyse treatment effects in the indi-
vidual trials. We planned to use a fixed-effect model in the first
instance to combine the data. For any meta-analyses, for categori-
cal outcomes we planned to calculate typical estimates of RR and
RD, each with 95% CI; for continuous outcomes we planned to
calculate the MD if outcomes were measured in the same way be-
tween trials, and standardised mean difference (SMD) to combine
trials that measured the same outcome, but use different scales.
When we judged meta-analysis to be inappropriate, we planned
to analyse and interpret individual trials separately.
Subgroup analysis and investigation of heterogeneity
Providing sufficient data were available, we planned to explore
potential sources of clinical heterogeneity through the following a
priori subgroup analyses:
1. timing of nebulised surfactant administration: prophylactic,
early rescue (within the first two hours of life), late rescue (within
the first week of life), or very late rescue (after the first week of
life);
2. type of surfactant aerosol generator used (jet, ultrasonic or
vibrating membrane nebuliser);
3. aerosol particle diameter regardless of aerosol generator and
type of surfactant used (2 µm or less, greater than 2 µm in
diameter);
4. type of surfactant used (specialised surfactant made for
inhalation, other non-specialised surfactant) regardless of being
synthetic or natural;
5. route of administration (nasopharyngeal tube, laryngeal
airway, nasal prong or face mask);
6. type of surfactant used (synthetic, animal derived or
protein-containing synthetic);
7. gestational age at delivery (less than 28, 28 to 31, 32 to 34
and 35 or greater completed weeks’ gestation).
Sensitivity analysis
Where sufficient data were available, we planned to explore
methodological heterogeneity through the use of sensitivity anal-
yses, which will serve to test the degree of robustness of the re-
sults obtained by the meta-analysis. We planned to perform sensi-
tivity analyses through excluding trials of lower quality, based on
a lack of any of the following: allocation concealment, adequate
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randomisation, blinding of treatment, less than 10% loss to fol-
low-up. Sensitivity analysis for effect of losses would include an
analysis using LOCF and imputation analysis (as above).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
See: Characteristics of included studies; Characteristics of excluded
studies.
A total of five reports were considered for this review. Four were
eliminated because they did not involve random allocation, a con-
trol group, or both (Jorch 1997; Arroe 1998; Finer 2010) or did in-
volve infant-simulator only (Pearson 2005). One study (Berggren
2000) was included in the present review. Details of this study
are provided in the Characteristics of included studies table. No
ongoing trials were identified.
Included studies
Types of participants
Berggren 2000 enrolled 34 preterm infants, with 32 infants re-
ported who met inclusion criteria including clinically and radio-
logically diagnosed RDS, corrected gestational age < 36 weeks, age
two to 36 hours, arterio/alveolar oxygen tension ratio (a/A pO2)
0.15 to 0.22, fraction inspired oxygen (FiO2) needed to maintain
arterial oxygen saturation (SaO2) 85% to 95%; transcutaneous
partial pressure oxygen (tcpO2) 6 to 8 kPa tcpO2 6 to 8 kPa, par-
tial pressure oxygen (PaO2) 7.5 to 9 kPa > 0.4, and no evidence
of lung or cardiovascular malformation. Two infants were later
excluded because they did not fulfil the inclusion criteria.
Types of interventions
Berggren 2000 compared 480 mg of nebulised surfactant (Curo-
surf ) generated via jet aerosol generator (Aiolos®, Karlstad, Swe-
den) and given via nCPAP equipment versus no treatment. There
was no standard ’failure criteria’, but in most cases a/A pO2 < 0.15
was considered as an indication for intubation and ventilation.
Types of outcomes measures
Berggren 2000 reported the following:
• a/A pO2 at 0, 2, 4, 6 and 12 hours post-randomisation;
• air leak;
• requirement of mechanical ventilation;
• duration of mechanical ventilation;
• duration of CPAP;
• duration of oxygen supplement;
• PDA;
• pathological cerebral ultrasound at one week;
• CLD.
Neurodevelopmental disability and some of the pre-specified sec-
ondary outcome measures of the review were not reported by
Berggren 2000.
Excluded studies
No other randomised, cluster-randomised or quasi-RCTs were
identified for exclusion from the review. Four observational non-
randomised and non-controlled studies were identified and ex-
cluded from this review (Jorch 1997; Arroe 1998; Pearson 2005;
Finer 2010).
Risk of bias in included studies
The single included study (Berggren 2000) was at moderate risk
of bias. Although the study reported an ITT analysis, the study
had unclear sequence generation and methods for maintaining
allocation concealment, lacked blinding and standardised failure
criteria, and had analyses of multiple respiratory end points. Rat-
ings of methodological quality are given in the Characteristics of
included studies table.
Allocation
Berggren 2000 randomised infants using a centralised scheme.
Method of sequence generation was not reported. Allocation was
concealed by using sealed envelopes.
Blinding
Berggren 2000 did not mask investigators, outcome assessors or
families to study group.
Incomplete outcome data
Berggren 2000 reported 2/34 (6%) infants excluded (one in each
group) post allocation as not meeting enrolment criteria.
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Selective reporting
Primary outcomes were not specific - described as ’safety and need
for mechanical ventilation’ (Berggren 2000).
Other potential sources of bias
Indication for intubation and ventilation (failure of intervention)
was not standardised, but in most cases a/A pO2 < 0.15 was con-
sidered as an indication for intubation and ventilation. pH was
lower in the treatment group compared to controls at randomisa-
tion (7.29 versus 7.32; P < 0.019).
Effects of interventions
Prophylactic treatment of preterm infants with
nebulised surfactant versus no treatment
No studies were found that enrolled infants at risk of RDS irre-
spective of the need for respiratory support or diagnosis of RDS.
Treatment of RDS with nebulised surfactant versus
no treatment (Comparison 1)
One study compared treatment of RDS with nebulised surfactant
versus no treatment (Berggren 2000).
Primary outcome measures
Chronic lung disease at 36 weeks’ postmenstrual age
Berggren 2000 reported no significant difference in CLD (32 in-
fants; RR 5.00; 95% CI 0.26 to 96.59) (Analysis 1.1). Test for
heterogeneity not applicable.
Mortality and neurodevelopmental outcome were not reported.
Secondary outcome measures
Berggren 2000 reported no significant difference in mechanical
ventilation (RR 1.20; 95% CI 0.46 to 3.15) (Analysis 1.2), air
leak (RR 1.00; 95% CI 0.30 to 3.32) (Analysis 1.3), PDA (RR
1.50; 95% CI 0.29 to 7.81) (Analysis 1.4) or pathological cere-
bral ultrasound at one week (RR 0.29; 95% CI 0.01 to 6.50)
(Analysis 1.5). Berggren 2000 reported no significant difference
in median days of IPPV (intervention six days versus control five
days), CPAP (intervention seven days versus control six days) and
oxygen (intervention 15 days versus control seven days). Test for
heterogeneity not applicable.
Other secondary outcome measures were not reported.
Subgroup analyses
The following subgroup analyses were pre-specified. As only one
study reported data, the outcomes are as reported above.
1. Timing of nebulised surfactant administration:
prophylactic, early rescue (within the first two hours of life), late
rescue (within the first week of life), or very late rescue (after the
first week of life): Berggren 2000 reported late rescue treatment
(mean age at treatment 19 hours).
2. Type of surfactant aerosol generator used (jet, ultrasonic or
vibrating membrane nebuliser): Berggren 2000 reported use of
jet aerosol generator (Aiolos®, Karlstad, Sweden).
3. Aerosol particle diameter regardless of aerosol generator and
type of surfactant used (2 µm or less, greater than 2 µm in
diameter): Berggren 2000 reported 99% of the particles in the
aerosol had a diameter < 2 µm.
4. Type of surfactant used (specialised surfactant made for
inhalation, other non-specialised surfactant) regardless of being
synthetic or natural: Berggren 2000 reported use of non-
specialised surfactant (Curosurf1, Chiesi Farmaceutici, Parma,
Italy).
5. Type of surfactant used (synthetic, animal derived or
protein-containing synthetic): Berggren 2000 reported use of
animal derived surfactant (Curosurf1, Chiesi Farmaceutici,
Parma, Italy).
6. Route of administration (nasopharyngeal tube, laryngeal
airway, nasal prong or face mask): Berggren 2000 reported
administration via nasal prongs using nasal CPAP circuit (Infant
Flow System1, Dansjo Medical AB, Bromma, Sweden).
7. Gestational age at delivery (less than 28, 28 to 31, 32 to 34
and 35 or greater completed weeks’ gestation): Berggren 2000
enrolled infants with median gestational age 31 weeks (range 28
to 34 weeks) and median birth weight 1603 to 1620 g (range
755 to 2855 g).
Sensitivity analysis
We planned to perform a sensitivity analysis based on the follow-
ing: inadequate randomisation, allocation concealment or blind-
ing of treatment, or greater than 10% loss to follow-up. Berggren
2000 reported unclear randomisation and allocation concealment,
and 6% losses post randomisation. Berggren 2000 reported no
masking of investigators, outcome assessors or families to study
group.
D I S C U S S I O N
Summary of main results
Only one small study was identified and found to be eligible for in-
clusion. This study enrolled preterm infants with RDS on nCPAP
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and reported no significant differences between nebulised surfac-
tant and control group in CLD, a/A pO2 1 to 12 hours after ran-
domisation, number of infants needing mechanical ventilation,
time on ventilator or CPAP, or duration of oxygen supplement.
No side effects of the nebulised surfactant therapy or aerosol in-
halation were noted.
Overall completeness and applicability of
evidence
The single small study included in the review reported outcomes
for 32 preterm infants with RDS on nCPAP and used nebulised
surfactant as treatment of established RDS. The data are largely
applicable to late treatment of established RDS in relatively mature
preterm infants. However, the study was underpowered to detect
important clinical benefits and harms of nebulised surfactant for
treatment of RDS. Furthermore, the study is of moderate risk of
bias.
No study was found that examined the effect of nebulised surfac-
tant administration for prevention of RDS (e.g. at resuscitation)
or early treatment of RDS in keeping with the known benefits of
prophylactic (Rojas-Reyes 2012) and early surfactant treatment
(Stevens 2007) in very preterm infants.
Quality of the evidence
The single included study (Berggren 2000) was of moderate risk
of bias. The study was unblinded, had unclear sequence genera-
tion, lacked standard definition for failure criteria (intubation and
ventilation) and had analysis of multiple respiratory end points.
Potential biases in the review process
An extensive search for published and unpublished literature was
performed including searches of trial registries for ongoing studies.
Two review authors independently assessed eligibility, study qual-
ity and extracted data. Agreement was reached through consensus.
Agreements and disagreements with other
studies or reviews
Berggren 2000 and Arroe 1998; demonstrated no beneficial effects
of nebulised surfactant, either during the period of nebulisation
or after the nebulisation. The discrepancy between these negative
results and other pilot observations (Jorch 1997; Pearson 2005;
Finer 2010) might be attributed to multiple factors:
• excessive loss of aerosolised surfactant in the nCPAP device:
Jorch 1997 reported successful treatment of RDS by aerosolised
surfactant using a jet nebuliser and delivery of the aerosol via a
nasopharyngeal tube. This is may raise the issue of excessive loss
when using nCPAP;
• size of the particles in the generated aerosol: however a
diameter < 2 µm as used by Berggren 2000 should be ideal for
deposition in peripheral airspaces;
• the effectiveness of delivery of aerosolised surfactant: the
effectiveness of delivery of aerosolised surfactant depends on the
type of aerosol generator (jet, ultrasonic or vibrating membrane
nebuliser). Arzhavitina 2010 hypothesise that a vibrating
membrane nebuliser is the best device for substances with surface
activity such as surfactant, as the residual volume in the device is
minimal and the substance output maximal. These results still
need confirmation by in vivo studies;
• timing of nebulised surfactant administration: for
endotracheal administration prophylactic (Soll 1998) and early
surfactant treatment (Soll 1999) have been demonstrated to be
more beneficial.
A non-systematic review of literature by Mazela 2007 concluded
that nebulised surfactant is a potentially beneficial strategy for
non-invasive surfactant delivery and further studies are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A single underpowered study of jet-nebulised animal-derived sur-
factant in preterm infants did not detect any benefits or harms in
preterm infants with established RDS on CPAP. There are insuffi-
cient data to support or refute its use in clinical practice. Nebulised
surfactant administration should be limited to clinical trials.
Implications for research
Adequately powered trials with appropriately designed delivery
systems are required to determine the effect of nebulised surfactant
administration for prevention or treatment of RDS in preterm in-
fants. Studies should measure short- and long-term outcomes pre-
specified in this review. Given the evidence for prophylactic and
early surfactant administration, trials should enrol infants early in
the course of respiratory illness.
Currently there are no ongoing registered trials for nebulised sur-
factant with ClinicalTrials.gov (searched 27 January 2012).
A C K N O W L E D G E M E N T S
As part of the pre-publication editorial process, this protocol has
been commented on by three peers (an editor and two referees
who are external to the editorial team) and the Group’s Statistical
Adviser.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berggren 2000
Methods Multicentre RCT
Participants Preterm infants who fulfilled the following enrolment criteria:
• corrected gestational age < 36 weeks
• age 2 to 36 hours
• clinically and radiologically diagnosed progressive RDS
• a/A pO2 0.15 to 0.22
• FiO2 needed to maintain SaO2 85% to 95%; tcpO2 6 to 8 kPa and PaO2 7.5 to 9
kPa
• No evidence lung or cardiovascular malformation
Infants were excluded if they did not fulfil the above criteria
Interventions Nebulised surfactant group (N = 17): received nCPAP according to normal clinical
routines. In addition, total of 480 mg of nebulised surfactant (Curosurf ) was generated
via jet aerosol generator (Aiolos®, Karlstad, Sweden) and given via nCPAP equipment.
Surfactant was diluted to 20 mg/mL before nebulisation, and 5-mL portions of the
diluted material were aerosolised alternating with 2-mL portions of saline. The procedure
took around 3 hours
Standard protocol (N = 17): received nCPAP alone, without nebulised surfactant. Placebo
treatment with, for instance, saline, was considered unethical and therefore not applied
Indication for intubation and ventilation was not standardised, but in most cases a/A
pO2 < 0.15 was considered as indication for intubation and ventilation
Outcomes Outcomes included:
• a/A pO2 at 0, 1, 2, 4, 6 and 12 hours post-randomisation
• air leak
• requirement of mechanical ventilation
• duration of mechanical ventilation
• duration of CPAP
• duration of oxygen supplement
• PDA
• pathological cerebral ultrasound at 1 week
• chronic lung disease
Notes Study sponsorship not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Centralised randomisation. Method of sequence generation not
reported
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Berggren 2000 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation using sealed envelopes kept on neonatal ward. Num-
bering and opaqueness not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No placebo used, blinding of outcome assessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/34 (6%) infants excluded (1 in each group) post allocation as
not meeting enrolment criteria
Selective reporting (reporting bias) Unclear risk Primary outcomes not specific - ’safety and need for mechanical
ventilation’
Other bias High risk Indication for intubation and ventilation was not standardised,
but in most cases a/A pO2 < 0.15 was considered as indication
for intubation and ventilation. pH was lower in the treatment
group compared to controls at randomisation (7.29 versus 7.32;
P < 0.019)
a/A pO2: arterio/alveolar oxygen tension ratio; CLD: chronic lung disease; nCPAP: nasal continuous positive airway pressure; PDA:
patent ductus arteriosus; RCT: randomised controlled trial; RDS: respiratory distress syndrome
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arroe 1998 Observational non-randomised and non-controlled study
Finer 2010 Observational non-randomised and non-controlled study
Jorch 1997 Observational non-randomised and non-controlled study
Pearson 2005 Observational non-randomised and non-controlled study involving infant-simulator
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D A T A A N D A N A L Y S E S
Comparison 1. Treatment of RDS with nebulised surfactant versus no treatment




participants Statistical method Effect size
1 Chronic lung disease 1 32 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 96.59]
2 Mechanical ventilation 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.2 [0.46, 3.15]
3 Air leak 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.30, 3.32]
4 Patent ductus arteriosus 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.29, 7.81]
5 Pathological cerebral ultrasound
at 1 week
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 6.50]
Analysis 1.1. Comparison 1 Treatment of RDS with nebulised surfactant versus no treatment, Outcome 1
Chronic lung disease.
Review: Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
Comparison: 1 Treatment of RDS with nebulised surfactant versus no treatment
Outcome: 1 Chronic lung disease
Study or subgroup Nebulised surfactant No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berggren 2000 2/16 0/16 100.0 % 5.00 [ 0.26, 96.59 ]
Total (95% CI) 16 16 100.0 % 5.00 [ 0.26, 96.59 ]
Total events: 2 (Nebulised surfactant), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Treatment of RDS with nebulised surfactant versus no treatment, Outcome 2
Mechanical ventilation.
Review: Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
Comparison: 1 Treatment of RDS with nebulised surfactant versus no treatment
Outcome: 2 Mechanical ventilation
Study or subgroup Nebulised surfactant No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berggren 2000 6/16 5/16 100.0 % 1.20 [ 0.46, 3.15 ]
Total (95% CI) 16 16 100.0 % 1.20 [ 0.46, 3.15 ]
Total events: 6 (Nebulised surfactant), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.3. Comparison 1 Treatment of RDS with nebulised surfactant versus no treatment, Outcome 3
Air leak.
Review: Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
Comparison: 1 Treatment of RDS with nebulised surfactant versus no treatment
Outcome: 3 Air leak
Study or subgroup Nebulised surfactant No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berggren 2000 4/16 4/16 100.0 % 1.00 [ 0.30, 3.32 ]
Total (95% CI) 16 16 100.0 % 1.00 [ 0.30, 3.32 ]
Total events: 4 (Nebulised surfactant), 4 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Treatment of RDS with nebulised surfactant versus no treatment, Outcome 4
Patent ductus arteriosus.
Review: Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
Comparison: 1 Treatment of RDS with nebulised surfactant versus no treatment
Outcome: 4 Patent ductus arteriosus
Study or subgroup Nebulised surfactant No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berggren 2000 3/16 2/16 100.0 % 1.50 [ 0.29, 7.81 ]
Total (95% CI) 16 16 100.0 % 1.50 [ 0.29, 7.81 ]
Total events: 3 (Nebulised surfactant), 2 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.5. Comparison 1 Treatment of RDS with nebulised surfactant versus no treatment, Outcome 5
Pathological cerebral ultrasound at 1 week.
Review: Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome
Comparison: 1 Treatment of RDS with nebulised surfactant versus no treatment
Outcome: 5 Pathological cerebral ultrasound at 1 week
Study or subgroup Nebulised surfactant No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berggren 2000 0/14 1/12 100.0 % 0.29 [ 0.01, 6.50 ]
Total (95% CI) 14 12 100.0 % 0.29 [ 0.01, 6.50 ]
Total events: 0 (Nebulised surfactant), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
#1 exp pregnancy
#2 exp infant premature
#3 exp infant newborn
#4 exp obstetric labor premature
#5 exp premature birth
#6 pregnan*.mp OR prematur*.mp OR preterm.mp OR neonat*.mp OR infant*.mp OR newborn.mp
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 aerosoli*.mp
#9 nebuli*.mp
#10 #8 OR #9
#11 exp pulmonary surfactants
#12 surfactant*.mp OR Beractant.mp OR Poractant.mp OR Curosurf.mp OR Survanta.mp OR Exosurf.mp OR Lucinactant.mp OR
Aerosurf.mp
#13 #11 OR #12
#14 #7 AND #10 AND #13
H I S T O R Y
Protocol first published: Issue 1, 2010
Review first published: Issue 10, 2012
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